J&J to spin off orthopedics business, raises full-year forecast

Johnson & Johnson reported third-quarter earnings and sales that exceeded analyst expectations, prompting the company to raise its 2025 sales forecast to $93.5 billion-$93.9 billion. Concurrently, J&J announced plans to spin off its orthopedics business, DePuy Synthes, within 18-24 months, marking its second major divestiture since 2023. This strategic move aims to sharpen J&J's focus on higher-growth, higher-margin areas like oncology and immunology, with management indicating the orthopedics unit's future innovation is better pursued externally, leading to a nearly 2% rise in J&J shares in premarket trading.

Analysis

Johnson & Johnson reported robust third-quarter results, with adjusted earnings of $2.80 per share and sales of $23.99 billion, both surpassing analyst expectations of $2.76 and $23.75 billion, respectively. This strong performance, driven by 6.8% year-over-year growth in both pharmaceuticals ($15.56 billion) and medical devices ($8.43 billion), led the company to raise its 2025 product revenue forecast to $93.5 billion-$93.9 billion, exceeding prior guidance by $300 million and analyst estimates of $93.4 billion. Shares reacted positively, rising nearly 2% in premarket trading.

Concurrently, J&J announced plans to spin off its orthopedics business, DePuy Synthes, within 18 to 24 months, marking its second major divestiture since 2023. The orthopedics unit, which generated approximately $9.2 billion last year (10% of total revenue), is targeted for a tax-free separation.

This strategic move aims to sharpen J&J's focus on higher-growth, higher-margin segments such as oncology, immunology, and neuroscience. CFO Joe Wolk indicated that the next phase of innovation for the orthopedics business is better pursued externally, suggesting a strategic reallocation of capital and management attention towards core pharmaceutical and medical device growth drivers.

Key Decisions for Investors

• Investors should assess J&J's strengthened financial outlook and strategic pivot towards higher-growth, higher-margin segments post-spin-off
• Monitor the execution of the DePuy Synthes spin-off for potential value unlocking and its impact on J&J's consolidated financial profile
• Evaluate the long-term implications of this restructuring on J&J's competitive positioning within the pharmaceutical and medical device markets